Informed adherence: the need for shared medical decision making.

Screening tests for colon cancer, breast cancer, and elevated serum cholesterol are widely advocated and included in some practice guidelines. Failure to complete these tests is regarded as patient noncompliance. The purpose of this paper is to review noncompliance with screening tests from the perspective of a traditional biomedical model and an outcomes model. According to the traditional biomedical model, compliance with screening tests is necessary to identify disease at an early stage and to initiate treatment. In contrast, the outcomes model argues that patients and providers should engage in activities that maximize benefit from the patient's perspective. Screening may lead to significant increases in case identification and in treatment rates. However, screening might also identify "pseudodisease," defined as disease that is not clinically important. For some diagnostic tests, cases of pseudodisease far exceed cases of clinically meaningful disease. The outcomes model suggests shared medical decision making in which uncertainties surrounding tests are disclosed to patients. Using information about the risks and expected health outcomes of screening and treatment, patients can participate in decisions about their own health care. Control Clin Trials 2000;21:233S-240S

[1]  L. Epstein.  The direct effects of compliance on health outcome. , 1984, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[2]  A. Feinstein,et al.  The role of diagnostic inconsistency in changing rates of occurrence for coronary heart disease. , 1992, Journal of clinical epidemiology.

[3]  R. Dinsmore,et al.  Interobserver Variability in Coronary Angiography , 1976, Circulation.

[4]  R. Kaplan.  Decisions about prostate cancer screening in managed care. , 1997, Current opinion in oncology.

[5]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[6]  S. Kaplan,et al.  Assessing the Effects of Physician-Patient Interactions on the Outcomes of Chronic Disease , 1989, Medical care.

[7]  M. Becker.  Patient adherence to prescribed therapies. , 1985, Medical care.

[8]  K. McPherson,et al.  Are Randomized Controlled Trials Controlled? Patient Preferences and Unblind Trials , 1997, Journal of the Royal Society of Medicine.

[9]  J. Wennberg.  Presidential Guest Speaker: Practice Variations and the Challenge to Leadership , 1996 .

[10]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[11]  D. Verrilli,et al.  The impact of diagnostic testing on therapeutic interventions. , 1996, JAMA.

[12]  R. Kaplan.  Behavioral epidemiology, health promotion, and health services. , 1985, Medical care.

[13]  J. Wennberg,et al.  Understanding geographic variations in health care delivery. , 1999, The New England journal of medicine.

[14]  J. Wennberg.  Practice variations and the challenge to leadership. , 1996, Spine.

[15]  F. J. Fowler,et al.  Methodological Issues in Measuring Patient‐Reported Outcomes: The Agenda of the Work Group on Outcomes Assessment , 1994, Medical care.

[16]  C. Coley,et al.  CLINICAL GUIDELINES: PART II: Early Detection of Prostate Cancer: Part II , 1997, Annals of Internal Medicine.

[17]  T. Takaro,et al.  Observer Agreement in Evaluating Coronary Angiograms , 1975, Circulation.

[18]  S J Schnitt,et al.  Interobserver Reproducibility in the Diagnosis of Ductal Proliferative Breast Lesions Using Standardized Criteria , 1992, The American journal of surgical pathology.

[19]  C. Mulrow,et al.  Colorectal cancer screening: clinical guidelines and rationale. , 1997, Gastroenterology.

[20]  P. Scardino,et al.  Early detection of prostate cancer. , 1989, The Urologic clinics of North America.

[21]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[22]  B. Golomb.  Cholesterol and Violence: Is There a Connection? , 1998, Annals of Internal Medicine.

[23]  Russell S. Kirby,et al.  The Dartmouth Atlas of Health Care , 1998 .

[24]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.